Effect of Blastocyst Morphology and Developmental Speed on Transfer Strategy for Grade “C” Blastocyst in Vitrified-Warmed Cycles

Yuxia He  
Third Affiliated Hospital of Guangzhou Medical College

Shiping Chen  
Third Affiliated Hospital of Guangzhou Medical College

Jianqiao Liu  
Third Affiliated Hospital of Guangzhou Medical College

Xiangjin Kang  
Third Affiliated Hospital of Guangzhou Medical College

Haiying Liu (✉ liuhaiying0606@163.com)  
The Third Affiliated Hospital of Guangzhou Medical University

Research

Keywords: poor-quality blastocyst, development speed, morphology, live birth rate, neonatal outcomes

DOI: https://doi.org/10.21203/rs.3.rs-143382/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** High-quality single blastocyst transfer (SBT) is increasingly recommended to patients because of its acceptable pregnancy outcomes and significantly reduced multiple pregnancy rate compared to double blastocyst transfer (DBT). However, there is no consensus on whether this transfer strategy is also suitable for poor-quality blastocysts. Moreover, the effect of the development speed of poor-quality blastocysts on pregnancy outcomes has been controversial. Therefore, this study aimed to explore the effects of blastocyst development speed and morphology on pregnancy and neonatal outcomes during the frozen embryo transfer (FET) cycle of poor-quality blastocysts and to ultimately provide references for clinical transfer strategies.

**Methods:** A total of 2,038 FET cycles of poor-quality blastocysts were analyzed from January 2014 to December 2019 and divided based on the blastocyst development speed and number of embryos transferred: the D5-SBT (n=476), D5-DBT (n=365), D6-SBT (n=730), and D6-DBT (n=467) groups. The SBT group was further divided based on embryo morphology: D5-AC/BC (n=407), D5-CA/CB (n=69), D6-AC/BC (n=580), and D6-CA/CB (n=150).

**Results:** When blastocysts reach the same development speed, the live birth and multiple pregnancy rates of DBT were significantly higher than those of SBT. Moreover, there was no statistical difference in the rates of early miscarriage and live birth between the AC/BC and CA/CB groups. When patients in the SBT group were stratified by blastocyst development speed, the rates of clinical pregnancy (42.44% vs. 20.82%) and live birth (32.35% vs. 14.25%) of D5-SBT group were significantly higher than those of D6-SBT group. Furthermore, for blastocysts in the same morphology group (AC/BC or CA/CA group), the rates of clinical pregnancy and live birth in the D5 group were also significantly higher than those of D6 group.

**Conclusion:** For poor-quality D5 blastocysts, SBT can be recommended to patients because of acceptable pregnancy outcomes and significantly reduced multiple pregnancy rate compared with DBT. For poor-quality D6, the DBT strategy is recommended to patients to improve pregnancy outcomes. When blastocysts reach the same development speed, the transfer strategy of selecting blastocyst with inner cell mass “C” or blastocyst with trophectoderm “C” does not affect the pregnancy and neonatal outcomes.

Introduction

The *in vitro* fertilization–embryo transfer (IVF-ET) technology is widely used worldwide and benefits many couples with infertility. However, multiple embryo transfer resulting from this technology led to an increased incidence of multiple pregnancy, which is considered the most common adverse event associated with the IVF-ET technology [1]. Multiple pregnancy is associated with an increased risk of maternal and fetal complications, including miscarriage, preeclampsia, hypertension, preterm labor, and perinatal morbidity and mortality [2, 3]. Therefore, employing the strategy of single embryo transfer is an effective measure to minimize the incidence of multiple pregnancy for infertile patients undergoing assisted reproductive technology (ART).

Blastocyst transfer could yield higher implantation and clinical pregnancy rates compared with cleavage stage embryo transfer [4]. Moreover, single high-quality blastocyst transfer not only yields an acceptable pregnancy outcome compared to double blastocyst transfer (DBT) but also significantly reduces the incidence of multiple pregnancy [5-7]. Therefore, the practice of single high-quality blastocyst transfer is gradually accepted by physicians around the world, which could reduce maternal complications and improve perinatal outcomes. However, for patients achieving only poor-quality blastocysts, DBT is usually recommended to increase the live birth rate. The multiple pregnancy rate of double poor-quality blastocysts can still reach 33% in frozen embryo transfer (FET) cycles [8]. Our previous studies showed that the multiple pregnancy rate of double poor-quality D5 blastocysts is as high as 30–50%, and suggested that single poor-quality D5 blastocyst transfer can be recommended for patients only with grade “C” blastocyst, regardless of age [9]. However, this research did not mention
whether the developmental potential of blastocysts with inner cell mass (ICM) “C” is different from that of blastocysts with trophectoderm (TE) “C” and the effect of different selection strategy on pregnancy and neonatal outcomes.

When blastocysts reach the same grade, it is unclear whether we should focus on the embryo development speed before transfer. A recent study illustrated the impact of embryo development speed on pregnancy outcomes based on blastocyst morphology [10]. Therefore, the strategy of blastocyst transfer should be determined according to the embryo development speed and morphology. To the best of our knowledge, few studies assessed the effects of the number of blastocysts transferred, blastocyst morphology, and development speed on neonatal outcomes, solely in grade “C” blastocyst. Therefore, in the present study, we explored the influence of blastocyst morphology and development speed on vitrified-warmed blastocyst transfer pregnancy and neonatal outcomes and ultimately provided evidence for the implementation of poor-quality blastocyst transfer strategies.

Materials And Methods

Study population and grouping

A retrospective study that included 2,038 FET cycles with poor-quality blastocysts was conducted at the Reproductive Medicine Center of the Third Affiliated Hospital of Guangzhou Medical University from January 2014 to December 2019. The inclusion criteria were as follows: (1) poor-quality blastocyst transfer; (2) age ≤ 40 years; and (3) endometrial thickness ≥ 7 mm. The exclusion criteria were as follows: (1) donated oocytes or embryos; (2) cycles with preimplantation genetic testing (PGT); (3) transferred blastocysts frozen on day 7; (4) stage III to IV endometriosis or adenomyosis; (5) known uterine anomalies including intrauterine adhesion, septal uterine cavity, endometrial polyps, and submucosal fibroid; (6) untreated hydrosalpinx; (7) uncontrolled endocrine and/or immune disorders or other systemic diseases, including hypertension, diabetes, thyroid disease, hyperprolactinemia, antiphospholipid syndrome, and systemic lupus erythematosus.

Patients were categorized into four groups according to blastocyst development speed and the number of embryos transferred, namely the D5-SBT group (n=476), D5-DBT group (n=365), D6-SBT group (n=730), and D6-DBT group (n=467). Patients in the SBT group were again divided into four subgroups based on the blastocyst morphology: D5-AC/BC (n=407), D5-CA/CB (n=69), D6-AC/BC (n=580), and D6-CA/CB (n=150). The study was approved by the local Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University.

Blastocyst quality assessment and vitrification

Blastocysts were scored according to the Gardner grading system [11] and recorded as high-quality blastocysts if they reached at least an expansion stage 3 with A or B for ICM and TE. The embryos included in this study were all poor-quality blastocysts, which are defined as at least an expansion stage 3 with ICM “C” or TE “C.” In all FET cycles, no more than two blastocysts were transferred.

The precise vitrification and thawing protocol of the blastocysts was carried out according to the manufacturer’s instructions. Briefly, blastocyst vitrification was carried out using a Cyrotop carrier system (Kitazato Biophama Co. Ltd.. Shizuoka. Japan), in conjunction with DMSO-EG-S as a cryoprotectant. For thawing, embryos were transferred into dilution solution in a sequential manner (1 M-0.5 M-0.25 M-0 M sucrose).

Endometrial preparation for the FET cycle embryo transfer

Endometrial preparation for the FET cycle in this study was achieved using natural cycle (NC) or hormone replacement treatment (HRT) programs. In short, NC was applied for patients with regular menstrual cycles and ovulation. The ovulation in the NC protocol was determined by monitoring the follicular development with transvaginal ultrasonography and hormone levels. HRT was applicable for patients with irregular menstrual cycles or poor endometrium development in NC. The patients...
were treated with daily oral estradiol valerate tablets (Progynova, Bayer, Germany) from the second to the fourth day of menstruation. When endometrial thickness reached 7 mm or thicker, exogenous progesterone was administered daily.

One or two thawed blastocysts were transferred on the sixth day after ovulation or progesterone exposure using a soft-tipped Wallace (Portex Ltd., Hythe, United Kingdom) catheter under ultrasound guidance. All patients received luteal support with progesterone after embryo transfer and continued to 10 weeks of gestational age if a pregnancy occurred.

**Outcome parameters**

The primary outcome of this study was the live birth rate (LBR). Secondary endpoints included rates of implantation, clinical pregnancy, multiple pregnancy, spontaneous miscarriage, and neonatal outcomes. Neonatal outcomes included preterm birth, birth weight, height, and low birth weight.

Live birth was defined as the delivery of any viable infant who was 28 weeks of gestation or older, and twins delivered by one mother were calculated as one live birth. Clinical pregnancy was defined as the presence of gestational sac transvaginal ultrasound at 6–8 weeks of gestation. Early miscarriage was defined as a spontaneous pregnancy demise at less than 12 weeks of gestation. Preterm birth was defined as a delivery before completing 37 weeks of gestation, and low birth weight was defined as a birth weight less than 2,500 g.

**Statistical Analysis**

The statistical analysis was performed with the use of the Statistical Package for Social Science (SPSS) version 22.0. The baseline characteristics were expressed as the mean ± standard deviation (SD), and differences in variables were compared using Student's t-test or one-way analysis of variance (ANOVA). Categorical variables were described as frequencies and percentages and compared using the chi-square test and Fisher's exact test when the number of events was less than 5. A P-value < 0.05 was considered statistically significant.

**Results**

A total of 2,038 FET cycles met the study inclusion criteria and were included in the analysis. All FET cycles were divided into four groups according to the blastocyst development speed and number of transferred embryo. There were 476 cycles included in the D5-SBT group, 365 cycles in the D5-DBT group, 730 cycles in the D6-SBT group, and 467 cycles in the D6-DBT group. Moreover, the patients in the SBT groups were sub-grouped by blastocyst morphology, namely D5-AC/BC, D5-CA/CB, D6-AC/BC, and D5-CA/CB groups.

Comparisons of pregnancy and neonatal outcomes of poor-quality blastocyst FET cycles between SBT and DBT groups stratified by blastocyst development speed are summarized in Table 1. When blastocysts reached the same development speed, there were no statistical differences between the SBT and DBT groups in patients’ age, body mass index (BMI), anti-mullerian hormone (AMH), infertility duration, proportion of endometrial preparation program, endometrial thickness, and rates of implantation, miscarriage, and ectopic pregnancy. For D5 poor-quality blastocysts, the rates of live birth and multiple pregnancy in the DBT group were significantly higher than those in the SBT group (46.03% vs. 32.35%, 39.91% vs. 3.96%). This conclusion is also valid for the D6 poor-quality blastocyst subgroup; however, the multiple pregnancy rate of the DBT group was approximately 19.21%, and the live birth rate was only 27.41%. The vast majority of twins were born prematurely (66.10% for D5, 61.11% for D6). In addition, 91.54% of low birth weight babies came from twins in the D5-DBT group, and 78.26% were from twins in the D6-DBT group. There was no significant difference between the SBT and DBT groups stratified by twin or singleton in terms of gestational age, newborn height and weight, and proportion of low birth weight infants. When the SBT group was stratified by development speed, there was no difference in patients’ age, BMI, and infertility duration between the D5-SBT and D6-SBT groups. However, rates of clinical pregnancy and live birth in the D5-SBT group were significantly higher than those of the D6-SBT group (42.44 % vs. 20.82 %, 32.35% vs. 14.25%).
Comparisons of pregnancy outcomes of single poor-quality blastocyst FET cycles between the AC/BC and CA/CB groups stratified by blastocyst development speed are presented in Table 2. When blastocysts were at the same development speed, there was no statistical difference in patients’ age, BMI, AMH, infertility duration, proportion of endometrial preparation, endometrial thickness, and rates of multiple pregnancy, miscarriage, ectopic pregnancy, and preterm birth between the AC/BC and CA/CB groups. The clinical pregnancy rate (43.73% vs. 34.78% for D5; 21.21% vs. 19.33% for D6) and live birth rate (33.17% vs. 27.54% for D5; 14.66% vs. 12.67% for D6) in the AC+BC group was slightly higher than that of the CA+CB group, but the difference was not statistically significant. When blastocysts in the same morphology group were stratified by development speed, there was no significant difference in age, BMI, infertility duration, and endometrial thickness in the D5 group compared with the D6 group. However, the rates of clinical pregnancy and live birth in the D6 group were significantly lower than those in the D5 group.

Table 3 displays the effect of blastocyst with ICM “C” or TE “C” on neonatal outcomes of single blastocyst transfer FET cycles. Considering the small number of twins, only singleton data were included in the analysis. When blastocysts in the same morphology group were stratified by development speed, they were divided into four groups. There was no significant difference in the gestational age, newborn weight, and height, and the proportion of low birth weight infants among those groups.

Discussion

This study explored the effect of poor-quality blastocyst development speed and morphology on pregnancy and neonatal outcomes, and ultimately provided references for poor-quality blastocyst transfer strategy in clinical practice. This study suggested that single D5 blastocyst could be preferentially recommended to patients with only poor-quality because of an acceptable live birth rate and significantly reduced multiple pregnancy rate compared with DBT. DBT was considered for D6 blastocysts to improve the live birth rate. When blastocyst reach the same development speed, the transfer of blastocyst with ICM “C” or blastocyst with TE “C” had no impact on pregnancy and neonatal outcomes.

Multiple pregnancy is a common iatrogenic complication of IVF-ET. Single embryo transfer is an effective and powerful measure to avoid iatrogenic multiple pregnancy. The strategy of single high-quality blastocyst transfer has been gradually accepted by reproductive clinicians because of its acceptable live birth rate and the significantly reduced multiple pregnancy rate, which could significantly improve perinatal outcomes [6]. Meanwhile, previous studies have shown that the live birth rate is approximately 47.6–64.08% and the multiple pregnancy rate is 30.7–49.66% for DBT composed of high-quality and poor-quality blastocysts [5, 9]. These studies indicated that the transfer of an additional poor-quality blastocyst does not negatively affect the implantation potential of high-quality blastocysts. Nevertheless, the addition of poor-quality blastocysts contributes to both live birth and multiple births. For patients without high-quality blastocysts, the strategy of DBT is generally recommended to improve the live birth rate. Research has reported that the multiple pregnancy rate of DBT in poor-quality blastocysts is still as high as 33% [8]. Dobson et al. showed that the live birth rate of single poor-quality blastocysts was similar to that of double poor-quality blastocysts, but the multiple pregnancy rate was significantly decreased in patients undergoing the FET cycle [8]. Our research results are different from this conclusion and showed that the rates of live birth and multiple pregnancy of DBT are significantly higher than those of SBT for poor-quality blastocysts. The live birth rate of the D5-SBT group could reach 32.35%, and 14.25% in the D6-SBT group. Therefore, the strategy of single poor-quality D5 blastocyst transfer can be suggested to reduce the multiple pregnancy rate. For poor-quality D6 blastocysts, there are few reports on whether single embryo transfer is also recommended.

The comparison of pregnancy outcomes between D5 and D6 blastocysts remains controversial. The differences in study results may be caused by blastocyst culture systems, frozen–thawed methods, different blastocyst culture strategies and methods, and highly subjective blastocyst scoring methods in different centers [12]. Ferreux et al. [13] revealed that the pregnancy outcomes following frozen-thawed blastocyst transfer are significantly lower with D6 than with D5 blastocyst regardless of embryo quality. Shen et al. [10] found that blastocyst frozen days (day 5 or 6) had no impact on live birth rate for AA/AB/BA blastocysts; however, those frozen on day 5 had significantly better live birth rates than those frozen on day 6.
for BB/BC/CB blastocysts. The results of this study are consistent with this and show that the rates of clinical pregnancy and live birth of patients in the D5-SBT group were significantly higher than those of the D6-SBT group for poor-quality blastocysts. Yang et al. [12] performed preimplantation genetic screening (PGS) on 237 blastocysts and found that blastocyst development speed had no effect on the euploid rate for high-quality blastocysts (55.2% vs. 55.3%, P > 0.05). The rates of euploid and clinical pregnancy in the D5 group were higher than those in the D6 group for poor-quality blastocysts. Other studies [14] found that delayed blastulation is not associated with increased aneuploidy rates, but this conclusion has not been further compared and analyzed when stratified by blastocyst quality. The above study results suggest that blastocyst development speed may have little predictive value for the developmental potential of high-quality blastocysts but may have a certain predictive value for poor-quality blastocysts. Therefore, DBT is recommended to increase the live birth rate for poor-quality D6 blastocysts, and the patient needs to be informed that there is a 14.06% (18/128) risk of multiple births.

The blastocyst grading scheme is usually based on the Gardner grading system. The parameters included the expansion degree and individual evaluation of the ICM and TE. The effect of blastocyst morphology parameters on pregnancy outcomes is controversial. Du et al. [15] found that the blastocyst expansion degree was the only indicator that predicted the live birth rate in both fresh and vitrified-warmed single blastocyst transfer cycles, and neither ICM nor TE grade was correlated with live birth rate. Subira et al. [16] showed that ICM, rather than TE, has a better predictive value for live birth in fresh SBT. Chen et al. [17] suggested that TE grading, but not ICM grading, was significantly associated with clinical pregnancy rate and live birth rate in FET cycles in a Chinese population. The inconsistency of these research results brought confusion to the blastocyst transfer strategy in clinical practice, whether we choose the blastocyst with a better ICM or the blastocyst with a better TE when selecting a single poor-quality blastocyst for transferring. This study found that there was no significant difference in the rates of clinical pregnancy, live birth, and early miscarriage between the AC/BC and CA/CB groups when blastocysts were at the same development speed. The early miscarriage rate of each group reached more than 20%, suggesting that both ICM and TE play an extremely important role in the whole process of embryo development.

In this study, patients with singleton births undergoing SBT were divided into four groups based on blastocyst development speed and morphology. The results showed that there was no significant difference in the gestational age, neonatal height and weight, and the proportion of low birth weight among the four groups. Although the live birth rate of D6 blastocysts is significantly lower than that of the D5 group whether for AC/BC or CA/CB blastocysts, but once persistent pregnancy is achieved, similar neonatal outcomes can be obtained. However, it cannot be ruled out that there is no statistically significant difference due to the small sample size. Additionally, Oron et al. [18] showed that pregnancy resulting from poor-quality embryos, whether at the cleavage or blastocyst stage, did not result in any obvious increased risk of adverse obstetric or perinatal outcomes compared with good-quality embryos. Similarly, Bouillon et al. [19] suggested that the main obstetric and perinatal outcomes of singletons after transfer of blastocysts with poor morphological characteristics were not associated with increased adverse obstetric and perinatal events. Therefore, the implementation of single poor-quality blastocyst transfer can reduce multiple pregnancy, improve perinatal maternal and infant outcomes, and obtain a similar perinatal outcome to that of high-quality embryos. This information could be important to reassure couples who conceive following the transfer of poor-quality embryos.

There are some limitations to this study. First, the sample size included in each group is uneven; therefore, the results of the study may be biased, and further research is needed to confirm the conclusion of this study. In addition, considering that ICM develops into the fetus, a lower ICM score may affect fetal development in the future. Therefore, embryo transfer strategies tend to choose blastocysts with better ICM for transfer in clinical practice, which may also be an important reason for the uneven sample size. However, as far as we know, the number of patients included in this study among each group was larger than that of other similar studies, making the results from this study valuable for guiding the transfer strategy of poor-quality blastocysts.
Conclusions

When blastocysts reach the same grade, we should focus on embryo development speed before the transfer for poor-quality blastocysts because the pregnancy outcomes of D5 blastocysts are significantly better than those of D6 blastocysts. For poor-quality D5 blastocysts, SBT could be recommended because of the acceptable live birth rate and significantly reduced multiple pregnancy rates compared to DBT. For poor-quality D6 blastocysts, DBT is recommended to improve pregnancy outcomes. Meanwhile, once a continuous pregnancy is reached, the blastocyst development speed and morphology do not affect neonatal outcomes.

Abbreviations

AMH: anti-mullerian hormone; ANOVA: one-way analysis of variance; ART: assisted reproductive technique; BMI: body mass index; DBT: double blastocyst transfer; FET: frozen embryo transfer; HRT: hormone replacement therapy; ICM: inner cell mass; ICSI: intracytoplasmic sperm injection; IVF-ET: in vitro fertilization and embryo transfer; LBR: live birth rate; NC: natural cycle; PGT: preimplantation genetic testing;

PGS: preimplantation genetic screening; SBT: single blastocyst transfer; SD: standard deviation; SPSS: statistical package for social science; TE: trophectoderm.

Declarations

Acknowledgments

The study was performed under the auspices of the IVF unit of the Third Affiliated Hospital of Guangzhou Medical University.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Animal studies

This article did not contain any studies with animals performed by any of the authors.

Funding

This study was supported by the National Natural Science Foundation of China (No.81801532, to HYL) and the Guangdong Basic and Applied Basic Research Foundation (No.2019A1515010755, to XJK).

Availability of data and materials:

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

HYL and YXH designed the research. YXH, SPC, JQL, XJK, and HYL analyzed the data. YXH, SPC, and HYL wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the ethics committee of the Third Affiliated Hospital of Guangzhou Medical University. Each patient has signed informed consent on obtaining and analyzing their clinical data prior to the initiation of IVF/ICSI-ET treatment.
Consent for publication

The author confirms that the work described has not been published before; that its publication has been approved by all co-authors; that its publication has been approved (tacitly or explicitly) by the responsible authorities at the institution where the work is carried out.

Competing interests

The authors declare that they have no competing interests.

References

1. European IVF-monitoring Consortium (EIM), European Society of Human Reproduction and Embryology (ESHRE), Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon J, Erb K, Mocanu E, et al. Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE. Hum Reprod. 2017;32:1957-73.

2. Pinborg A, Loft A, Schmidt L, Andersen AN. Morbidity in a Danish national cohort of 472 IVF/ICSI twins, 1132 non-IVF/ICSI twins and 634 IVF/ICSI singletons: health-related and social implications for the children and their families. Hum Reprod, 2003;18:1234-43.

3. Mullin CM, Fino ME, Talebian S, Krey LC, Licciardi F, Grifo JA. Comparison of pregnancy outcomes in elective single blastocyst transfer versus double blastocyst transfer stratified by age. Fertil Steril. 2010;93: 1837-43.

4. Zhu Q, Zhu J, Wang Y, Wang B, Wang N, Yin M, et al. Live birth rate and neonatal outcome following cleavage-stage embryo transfer versus blastocyst transfer using the freeze-all strategy. Reprod Biomed Online. 2019;38: 892-900.

5. Wang W, Cai J, Liu L, Xu Y, Liu Z, Chen J, et al. Does the transfer of a poor quality embryo with a good quality embryo benefit poor prognosis patients? Reprod Biol Endocrinol. 2018;16: 97.

6. Aldemir O, Ozelci R, Baser E, Kaplanoglu I, Dilbaz S, Dilbaz B, et al. Impact of Transferring a Poor Quality Embryo Along with a Good Quality Embryo on Pregnancy Outcomes in IVF/ICSI Cycles: a Retrospective Study. Geburtshilfe Frauenheilkd. 2020;80:844-50.

7. Hill MJ, Eubanks AE, Csokmay JM, Christy AY, Jahandideh S, DeCherney AH, et al. Is transferring a lower-quality embryo with a good-quality blastocyst detrimental to the likelihood of live birth? Fertil Steril. 2020;114: 338-45.

8. Dobson SJA, Lao MT, Michael E, Varghese AC, Jayaprakasan K. Effect of transfer of a poor quality embryo along with a top quality embryo on the outcome during fresh and frozen in vitro fertilization cycles. Fertil Steril. 2018;110:655-60.

9. Chen S, Du H, Liu J, Liu H, Li L, He Y. Live birth rate and neonatal outcomes of different quantities and qualities of frozen transferred blastocyst in patients requiring whole embryo freezing stratified by age. BMC Pregnancy Childbirth. 2020;20:655.

10. Shen X, Long H, Gao H, Guo W, Xie Y, Chen D, et al. The Valuable Reference of Live Birth Rate in the Single Vitrified-Warmed BB/BC/CB Blastocyst Transfer: The Cleavage-Stage Embryo Quality and Embryo Development Speed. Front Physiol. 2020;11:1102.

11. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73:1155-8.

12. Yang H, Yang Q, Dai S, Li G, Jin H, Yao G, et al. Comparison of differences in development potentials between frozen-thawed D5 and D6 blastocysts and their relationship with pregnancy outcomes. J Assist Reprod Genet. 2016;33:865-72.

13. Ferreux L, Bourdon M, Sallem A, Santulli P, Barraud-Lange V, Le Foll N, et al. Live birth rate following frozen-thawed blastocyst transfer is higher with blastocysts expanded on Day 5 than on Day 6. Hum Reprod. 2018;33:390-8.

14. Kroener L, Ambartsumyan G, Briton-Jones C, Dumesci D, Surrey M, MunneS, et al. The effect of timing of embryonic progression on chromosomal abnormality. Fertil Steril. 2012;98:876-80.
15. Du QY, Wang EY, Huang Y, Guo XY, Xiong YJ, YuYP, et al. Blastocoele expansion degree predicts live birth after single blastocyst transfer for fresh and vitrified/warmed single blastocyst transfer cycles. Fertil Steril. 2016;105:910-9.

16. Subira J, Craig J, Turner K, Bevan A, Ohuma E, McVeigh E, et al. Grade of the inner cell mass, but not trophectoderm, predicts live birth in fresh blastocyst single transfers. Hum Fertil (Camb). 2016;19:254-61.

17. Chen X, Zhang J, Wu X, Cao S, Zhou L, Wang Y, et al. Trophectoderm morphology predicts outcomes of pregnancy in vitrified-warmed single-blastocyst transfer cycle in a Chinese population. J Assist Reprod Genet. 2014;31:1475-81.

18. Oron G, Son WY, Buckett W, Tulandi T, Holzer H. The association between embryo quality and perinatal outcome of singletons born after single embryo transfers: a pilot study. Hum Reprod. 2014;29:1444-51.

19. Bouillon C, Celton N, Kassem S, Frapsauce C, Guérif F. Obstetric and perinatal outcomes of singletons after single blastocyst transfer: is there any difference according to blastocyst morphology? Reprod Biomed Online. 2017;35:197-207.

Tables

Table 1. Comparisons of poor-quality blastocyst FET cycles between SBT and DBT groups stratified by blastocyst development speed.
|                          | D5                      | D6                      |
|--------------------------|-------------------------|-------------------------|
| **Cycles (n)**           | 476                     | 365                     |
|                          | 730                     | 467                     |
| **female age (year)**    | 31.80±4.05              | 31.40±3.78              |
|                          | 0.105                   | 0.105                   |
|                          | 32.92±4.29              | 32.09±4.20              |
| **BMI (kg/m2)**          | 22.01±3.35              | 21.58±3.46              |
|                          | 0.909                   | 0.909                   |
|                          | 21.83±3.08              | 22.11±3.24              |
| **AMH (ng/ml)**          | 6.07±4.17               | 6.75±4.30               |
|                          | 0.333                   | 0.333                   |
|                          | 4.82±3.69               | 4.97±3.96               |
| **Duration of infertility (years)** | 4.78±3.24               | 4.71±3.04               |
|                          | 0.682                   | 0.682                   |
|                          | 4.86±3.21               | 4.82±3.20               |
| **Endometrial preparation (%)** | 0.525                   | 0.447                   |
| **Natural**              | 38.03                   | 35.89                   |
|                          | (181/476)               | (131/365)               |
|                          | 39.45                   | (288/730)               |
|                          | (174/467)               |                         |
| **HRT**                  | 61.97                   | 64.11                   |
|                          | (295/476)               | (234/365)               |
|                          | 60.55                   | (442/730)               |
|                          | (293/467)               |                         |
| **Endometrial thickness (mm)** | 8.97±1.39               | 8.91±1.42               |
|                          | 0.387                   | 0.387                   |
|                          | 8.95±1.44               | 9.05±1.46               |
| **Implantation rate**    | 42.44                   | 41.64                   |
|                          | (202/476)               | (304/730)               |
|                          | 0.785                   | 0.785                   |
|                          | 20.82                   | (152/730)               |
|                          | (209/934)               |                         |
| **Pregnancy rate**       | 42.44                   | 59.73                   |
|                          | (202/476)               | (218/365)               |
|                          | 0.000                   | 20.82*                  |
|                          | (152/730)               | (177/467)               |
| **Multiple pregnancy rate** | 3.96                    | 39.91                   |
|                          | (8/202)                 | (87/218)                |
|                          | 0.000                   | 2.63                    |
|                          | (4/152)                 | (34/177)                |
| **Early miscarriage rate** | 22.28                   | 19.72                   |
|                          | (45/202)                | (43/218)                |
|                          | 0.521                   | 0.521                   |
|                          | 27.63                   | (42/152)                |
|                          | (39/177)                |                         |
| **Miscarriage rate**     | 22.77                   | 22.48                   |
|                          | (46/202)                | (49/218)                |
|                          | 0.942                   | 30.92                   |
|                          | (47/152)                | (46/177)                |
| **Ectopic pregnancy rate** | 0.99                    | 0.46                    |
|                          | (2/202)                 | (1/218)                 |
|                          | 0.947                   | 0                      |
|                          | (0/152)                 | (1.13)                  |
|                          | (2/177)                 |                         |
|                          | AC/BC  | BC/AC  | P       | CA/CB   | CB/CA  | P       |
|--------------------------|--------|--------|---------|---------|--------|---------|
| Live birth rate          | 32.35  | 46.03  | 0.000   | 14.25* | 27.41  | 0.000   |
|                          | (154/476) | (168/365) |        | (104/730) | (128/467) |        |
| Singleton                | 31.30  | 29.86  | 0.654   | 14.25   | 23.55  | 0.000   |
|                          | (149/476) | (109/365) |        | (104/730) | (110/467) |        |
| Twin                     | 1.05   | 16.16  | 0.000   | 0.000   | 3.85   | 0.001   |
|                          | (5/476) | (59/365) |        | (0/730) | (18/467) |        |
| Preterm birth (37 weeks) | 9.74   | 32.14  | 0.000   | 6.67    | 17.19  | 0.015   |
|                          | (15/154) | (54/168) |        | (7/105) | (22/128) |        |
| Singleton                | 8.44   | 8.93   | 0.877   | 6.67    | 8.59   | 0.584   |
|                          | (13/154) | (15/168) |        | (7/105) | (11/128) |        |
| Twin                     | 1.30   | 23.21  | 0.000   | 0.000   | 8.59   | 0.001   |
|                          | (2/154) | (39/168) |        | (0/105) | (11/128) |        |
| Gestational age (weeks)  | 38.51±1.75 | 36.52±3.79 | 0.000   | 38.45±1.58 | 37.79±1.84 | 0.054   |
| Singleton                | 38.60±1.74 | 38.37±1.90 | 0.428   | 38.45±1.58 | 38.29±1.61 | 0.954   |
| Twin                     | 36.33±0.52 | 34.83±4.28 | 0.120   | /       | 36.18±1.60 | /       |
| Birth height (mm)        | 49.75±1.77 | 47.82±3.65 | 0.000   | 49.81±1.82 | 48.97±2.97 | 0.001   |
| Singleton                | 49.89±1.65 | 49.69±1.70 | 0.950   | 49.81±1.82 | 49.95±1.91 | 0.813   |
| Twin                     | 46.33±1.21 | 46.11±4.09 | 0.197   | /       | 45.55±3.56 | /       |
| Birth weight (kg)        | 3227.16±459.78 | 2736.0±665.34 | 0.000   | 3263.60±538.74 | 3026.75±599.13 | 0.101   |
| Singleton                | 3255.69±442.21 | 3169.31±468.53 | 0.944   | 3263.60±538.74 | 3207.98±527.65 | 0.547   |
| Twin                     | 2523.33±318.04 | 2339.42±564.46 | 0.294   | /       | 2445.74±420.85 | /       |
| Low birth weight (≤2500 g)| 8.18  | 31.28  | 0.000   | 3.85    | 15.75  | 0.003   |
|                          | (13/159) | (71/227) |        | (4/104) | (23/146) |        |
| Singleton                | 5.37   | 5.50   | 0.962   | 3.85    | 4.55   | 0.999   |
|                          | (8/149) | (6/109) |        | (4/104) | (5/110) |        |
| Twin                     | 50.0   | 55.08  | 0.999   | /       | 50.0   | /       |
|                          | (5/10) | (65/118) |        | (18/36) |        |        |

*P value <.05 compared to the D5-DBT group.

Table 2. Comparisons of FET cycles undergoing SBT between AC/BC and CA/CB groups stratified by blastocyst development speed.
|                                | D5               | D6               | P     | D5               | D6               | P     |
|--------------------------------|------------------|------------------|-------|------------------|------------------|-------|
| Cycles (n)                     | 407              | 69               | 0.503 | 580              | 150              | 0.242 |
| female age (year)              | 31.87±4.01       | 31.39±4.23       | 0.503 | 32.92±4.30       | 32.91±4.24       | 0.877 |
| BMI (kg/m2)                    | 22.01±3.38       | 22.02±3.17       | 0.875 | 21.81±2.97       | 21.91±3.46       | 0.242 |
| AMH (ng/ml)                    | 6.13±4.21        | 5.75±3.94        | 0.582 | 4.78±3.63        | 4.98±3.93        | 0.887 |
| Duration of infertility (years)| 4.75±3.24        | 4.95±3.26        | 0.692 | 4.87±3.21        | 4.84±3.22        | 0.721 |
| Endometrial preparation (%)    |                  | 0.838            |       |                  | 0.597            |       |
| Natural                        | 37.84            | 62.16            |       | 38.97            | 61.03            |       |
|                                | (154/407)        | (27/69)          |       | (226/580)        | (62/150)         |       |
| HRT                            | 39.13            | 60.87            |       | 41.33            | 58.67            |       |
|                                | (253/407)        | (42/69)          |       | (354/580)        | (88/150)         |       |
| Endometrial thickness (mm)     | 8.92±1.35        | 9.27±1.59        | 0.064 | 8.98±1.46        | 8.87±1.37        | 0.062 |
| Pregnancy rate                 | 43.73            | 34.78            | 0.164 | 21.21*           | 19.33*           | 0.614 |
|                                | (178/407)        | (24/69)          |       | (123/580)        | (29/150)         |       |
| Multiple pregnancy rate        | 3.93             | 4.17             | 0.999 | 2.44             | 3.45             | 0.575 |
|                                | (7/178)          | (1/24)           |       | (3/123)          | (1/29)           |       |
| Early miscarriage rate         | 22.47            | 20.83            | 0.856 | 27.64            | 27.59            | 0.995 |
|                                | (40/178)         | (5/24)           |       | (34/123)         | (8/29)           |       |
| Miscarriage rate               | 23.03            | 20.83            | 0.809 | 30.08            | 34.48            | 0.645 |
|                                | (41/178)         | (5/24)           |       | (37/123)         | (10/29)          |       |
| Ectopic pregnancy rate         | 1.12             | 0                | 0.999 | 0                | 0                | /     |
|                                | (2/178)          | (0/24)           |       | (0/123)          | (0/29)           |       |
| Live birth rate                | 33.17            | 27.54            | 0.355 | 14.66*           | 12.67*           | 0.535 |
|                                | (135/407)        | (19/69)          |       | (85/580)         | (19/150)         |       |
|                  | D5               | D6               |
|------------------|------------------|------------------|
|                  | AC/BC            | CA/CB            |
|                  | AC/BC            | CA/CB            |
| Cycles (n)       | 131              | 18               |
|                  | 85               | 19               |
| Gestational age (weeks) | 38.58±1.75          | 38.78±1.70          |
|                  | 38.52±1.67          | 38.35±0.93          |
| Birth height (mm) | 49.84±1.65          | 50.22±1.66          |
|                  | 49.83±1.69          | 49.82±2.40          |
| Birth weight (kg) | 3241.58±435.86      | 3357.61±486.69      |
|                  | 3271.43±561.47      | 3265.29±422.09      |
| Low birth weight(≤2500 g) | 5.34            | 5.56               |
|                  | 3.53              | 5.26               |
|                  | (7/131)           | (1/18)            |
|                  | (3/85)            | (1/19)            |

Note: only singleton data were included in the analysis.